Science

Elvina Almuradova: Immunotherapy for HPV-Associated Cancers

Elvina Almuradova/LinkedIn

Feb 22, 2025, 13:28

Elvina Almuradova: Immunotherapy for HPV-Associated Cancers

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared an article by Charalampos S. Floudas, et al. on LinkedIn:

“Immunotherapy for HPV-Associated Cancers.

A recent phase 1/2 clinical trial published in JAMA Oncology explores a novel combination immunotherapy for advanced HPV-associated cancers. The study evaluates the efficacy of PDS01ADC (IL-12 antibody-drug conjugate), bintrafusp alfa (PD-L1/TGF-β inhibitor), and PDS0101 (HPV-16 therapeutic vaccine) in previously treated patients.

Key findings:

36.7% response rate in immune checkpoint blockade–naive patients.
62.5% response rate in patients with HPV-16–positive tumors.
Promising antitumor activity and improved survival.

These results highlight the potential of this combination therapy, warranting further investigation.

Could this be a new standard for HPV-associated cancers?”

Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical Trial.

Authors: Charalampos S. Floudas, et al.

Elvina Almuradova: Immunotherapy for HPV-Associated Cancers

Bintrafusp Alfa cancer Charalampos S. Floudas clinical trial Elvina Almuradova European Institute of Oncology fight against cancer Global fight against cancer HPV immunotherapy JAMA Oncology OncoDaily Oncology PDS0101 PDS01ADC

Senator Edward Markley in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity